
JNJ Stock Forecast & Price Target
JNJ Analyst Ratings
Bulls say
Johnson & Johnson is a top pick for potential investors due to its sustainable focus and strong performance in both its MedTech and Vision divisions. With plans to separate its Ortho business in 2027 and a promising new product launch in TECNIS PureSee, JNJ is poised for continued growth. While there are potential risks to consider, JNJ's focus on double-digit sales growth and disciplined capital allocation make it a favorable investment choice with opportunities for expansion in the Asia Pacific region.
Bears say
Johnson & Johnson is currently facing multiple challenges, including potential litigation risks related to talc products and loss of exclusivity for certain drugs. These factors could weigh on the company's financial performance in the coming years, despite its strong position in the MedTech market and a diverse portfolio of products. Additionally, the company's M&A strategy may face headwinds, as it looks to make early-stage pharmaceutical deals in a highly competitive market. These factors contribute to a negative outlook on Johnson & Johnson's stock.
This aggregate rating is based on analysts' research of Johnson & Johnson and is not a guaranteed prediction by Public.com or investment advice.
JNJ Analyst Forecast & Price Prediction
Start investing in JNJ
Order type
Buy in
Order amount
Est. shares
0 shares